FDI-6 | FOXM1 inhibitor

Available Options

Size:PriceQuantity 
5 mg$80.00
25 mg$250.00
Request Quote / Bulk / Custom Size
Product Inquiry

FDI-6 (313380-27-7) selectively blocks FOXM1 binding to DNA (IC50 = 22.5 µM) in MCF-7 breast cancer cells and suppresses transcription of FOXM1 genes.1 It decreased cell proliferation, migration, and invasion in MDA-MB-231 and HS578T triple negative breast cancer cell lines.2 FDI-6 acted synergistically with olaparib to inhibit the growth of triple negative breast3 and pancreatic4 cancer cells. It was found to induce the mRNA expression of aryl hydrocarbon receptor genes with subsequent suppression of tumorsphere formation in MCF-7 cells.5 FDI-6 enhanced T cell activation, supported differentiation of CD8+ cells, and T cell-mediated killing of small cell lung cancer cells.6

References/Citations:

  1. Gormally et al. (2014), Suppression of the FOXM1 transcriptional program via novel small molecule inhibition; Nat. Commun., 5 5165
  2. Ulhaka et al. (2021), The Anticancer Effects of FDI-6, a FOXM1 Inhibitor, in Triple Negative Breast Cancer; Int. J. Mol. Sci., 22 6685
  3. Wang et al. (2021), FDI-6 inhibits the expression and function of FOXM1 to sensitize BRCA-proficient triple-negative breast cancer cells to Olaparib by regulating cell cycle progression and DNA damage repair; Cell Death Dis., 12 1138
  4. Wu et al. (2022), FDI-6 and olaparib synergistically inhibit the growth of pancreatic cancer by repressing BUB1, BRCA1 and CDC25A signaling pathways; Pharmacol. Res., 175 106040
  5. Yamashita et al. (2023), FDI-6, a FROXM1 inhibitor, activates the aryl hydrocarbon receptor and suppresses tumorsphere formation; Biochem. Biophys. Res. Commun., 639 29
  6. Khan et al. (2026), Targeting FOXM1 reshapes antitumor immunity to attenuate small cell lung cancer progression; Cancer Lett., 638 218160
313380-27-7, FDI-6, FDI-6 supplier, FDI6 supplier, FOXM1 inhibitor
Alternate Name:
NCGC00099374

Safety Data Sheet:

Download Safety Data Sheet

Product Data Sheet:

Download Product Data Sheet

Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications. Please note that we do not sell to individuals and that all orders placed by non-research organizations will incur a $20 restocking/refund fee

FDI-6 (313380-27-7) selectively blocks FOXM1 binding to DNA (IC50 = 22.5 µM) in MCF-7 breast cancer cells and suppresses transcription of FOXM1 genes.1 It decreased cell proliferation, migration, and invasion in MDA-MB-231 and HS578T triple negative breast cancer cell lines.2 FDI-6 acted synergistically with olaparib to inhibit the growth of triple negative breast3 and pancreatic4 cancer cells. It was found to induce the mRNA expression of aryl hydrocarbon receptor genes with subsequent suppression of tumorsphere formation in MCF-7 cells.5 FDI-6 enhanced T cell activation, supported differentiation of CD8+ cells, and T cell-mediated killing of small cell lung cancer cells.6

References/Citations:

  1. Gormally et al. (2014), Suppression of the FOXM1 transcriptional program via novel small molecule inhibition; Nat. Commun., 5 5165
  2. Ulhaka et al. (2021), The Anticancer Effects of FDI-6, a FOXM1 Inhibitor, in Triple Negative Breast Cancer; Int. J. Mol. Sci., 22 6685
  3. Wang et al. (2021), FDI-6 inhibits the expression and function of FOXM1 to sensitize BRCA-proficient triple-negative breast cancer cells to Olaparib by regulating cell cycle progression and DNA damage repair; Cell Death Dis., 12 1138
  4. Wu et al. (2022), FDI-6 and olaparib synergistically inhibit the growth of pancreatic cancer by repressing BUB1, BRCA1 and CDC25A signaling pathways; Pharmacol. Res., 175 106040
  5. Yamashita et al. (2023), FDI-6, a FROXM1 inhibitor, activates the aryl hydrocarbon receptor and suppresses tumorsphere formation; Biochem. Biophys. Res. Commun., 639 29
  6. Khan et al. (2026), Targeting FOXM1 reshapes antitumor immunity to attenuate small cell lung cancer progression; Cancer Lett., 638 218160